Tumor cells target metastases as they die
A new drug can eliminate cancer cells while training the immune system to destroy such cells throughout the body
Advertisement
Two junior research groups at Ruhr University Bochum, Germany, have developed a drug complex that kills cancer cells in such a clever manner that they raise a red flag as they die. They signal to the immune system that something is seriously wrong with this type of cell. This teaches the immune cells to destroy such cancer cells—even if they are not in the vicinity of the original tumor. This could remove metastases that develop at distant sites in the body. Dr. Johannes Karges from the Department of Chemistry and Biochemistry and Dr. Carlos Plaza-Sirvent from the Department of Medicine present their findings in the Journal of Medicinal Chemistry on July 17, 2025.
Uncommon: immunogenic cell death
90 percent of all deaths from cancer are due to metastases. This is why Karges and his team are looking for ways to train the immune system to target and eliminate cancer cells. They have found success with a drug that kills the cells in a sophisticated manner. “The gallium complex we developed penetrates the cells and, because of its special properties, causes oxidative stress in a certain cell organelle known as the endoplasmic reticulum,” he explains. “The cells then undergo immunogenic cell death, which only very few drugs can achieve.”
Immune system learns to identify cancer cells
Through this type of cell death, proteins from the endoplasmic reticulum and the cell nucleus are released to the outside and act as a strong warning signal to the immune system: Something is wrong here, these cells are harmful. This teaches the immune system to recognize the cancer cells as hostile and eliminate them throughout the body. This should also destroy metastases.
The two teams led by Johannes Karges and Carlos Plaza-Sirvent have successfully tested the active ingredient on cervical cancer cell lines. The next step is to package it in such a way that it accumulates specifically in cancer cells and is effective only there, and not in all cells of the body. Karges' research group has already developed various methods for this, for example, which active ingredients are activated by an external signal such as ultrasound or light.
Original publication
Zisis Papadopoulos, Yassin Antar, Irma-Sofie Dieter, Frank Peeters, Carlos Plaza-Sirvent, Johannes Karges: Gallium(III) Complex Induces Immunogenic Cell Death Hallmarks for Chemoimmunotherapy, in: Journal of Medicinal Chemistry, 2025
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
Edible, biodegradable fibers made from milk protein, cellulose - Sustainable food packaging, wound dressings, cosmetics, filtration and more are all areas in which work is showing promise
Siemens completes acquisition of Dotmatics - Acquisition expanding Siemens’ offerings into the life sciences industry
Waters and BD's Biosciences & Diagnostic Solutions Business to Combine - Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing
Researchers develop process to turn food waste into biodegradable plastic - New process uses bacteria
Turning poison into a source of energy - A research team lhas succeeded in genetically manipulating the microorganism T. kivui to metabolize carbon monoxide
Pigments that can do more - New discovery sheds light on the bacterial use of biomass with potential for biofuels and new antibiotics
Research team achieves breakthrough in environmentally friendly control of invasive pests - Solving a 35-year-old puzzle paves the way for sustainable control of insect pests worldwide
New Discovery in Enzyme Research: Water is the Key for Activity - Discovery could help to enhance the use of biocatalysts in industrial applications such as food processing or the production of biofuels
Synthesizing fine chemicals: Technological Advance in Production of Pharmaceuticals
Evotec announces sale of API manufacturing facility to Monacum Partners - New ownership committed to maintaining and growing the business
Rentschler Biopharma announces largest single investment at its headquarters in Germany - Construction of a new buffer media station in Laupheim
